Chemometric spectrophotometric methods for simultaneous estimation of metoprolol succinate and amlodipine besylate in their tablet formulation

Area under the curve and ratio difference spectrophotometric methods with evaluation of the greenness for simultaneous determination of olmesartan medoxomil and metoprolol succinate

The aim of this study is to develop and validate two simple spectrophotometric methods for simultaneous determination of metoprolol succinate (MET) and olmesartan medoxomil (OLM) in tablet form. Method (I) was area under the curve (AUC) method. This approach involved the measuring of the area over a variety of wavelengths. Two wavelength ranges; 213-230 nm and 244-266 nm were chosen for determination of MET and OLM, respectively. Method (II) was ratio difference spectrophotometricmethod. For determination of MET, the ratio spectra were generated using 15 μg/mL OLM as a divisor then the peak to trough amplitudes between 221 nm and 245 nm were displayed versus the corresponding concentrations of MET. For determination of OLM, the peak-to-peak amplitudes between 247 and 293 nm were chosen and found to be directly proportional to OLM concentrations using 15 μg/mL MET as a divisor. The linearity ranges were 2-30 μg/mL and 2-25 μg/mL for MET and OLM, respectively. The assay results showed good mean %recovery ± SD as well as good agreement with that of the reported method. The developed methods were validated according to ICH guidelines. The developed methods are accurate, precise, eco-friendly and could be applied successfully to estimate OLM and MET in their combined dosage form.

Coupling of synchronous fluorescence spectroscopy with derivative amplitude outcomes for simultaneous determination of metoprolol succinate and olmesartan medoxomil in combined pharmaceutical preparation: Application in spiked human plasma

For the first time a spectrofluorimetric method had been achieved for the concurrent analysis of metoprolol succinate (MET) and olmesartan medoxomil (OLM). The approach depended on assessing the first order derivative (¹D) of the synchronous fluorescence intensity of the two drugs in aqueous solution at Δλ of 100 nm. The amplitudes of ¹D at 300 nm and 347 nm were measured for MET and OLM, respectively. The linearity ranges were 100-1000 ng/mL and 100-5000 ng/mL for OLM and MET, respectively. This approach is uncomplicated, repetitive, quick, and affordable. The results of analysis had been statistically verified. The validation assessments were carried out following the recommendations of The International Council for Harmonization (ICH). This technique could be employed to assess marketed formulation. The method was sensitive with limits of detection (LOD) of 32 ng/ml and 14 ng/mL for MET and OLM, respectively. Limits of quantitation (LOQ) were 99 ng/ml for MET and 44 ng/mL for OLM. So it can be applied to determine both drugs in spiked human plasma within the linearity ranges of 100-1000 ng/mL for OLM and 100-1500 ng/mL for MET.

Utility of synchronous fluorimetry for the concurrent quantitation of metoprolol and ivabradine

Metoprolol combined with ivabradine have been determined up to nanogram level simultaneously relied on the synchronous fluorescence spectra. First derivative amplitudes of the synchronous spectrofluorimetric spectra are recorded at Δλ = 40 nm using ethanol as diluting solvent. Metoprolol can be measured at 286 nm which is the zero-crossing point of ivabradine, and the later can be measured at 296 nm. The calibration plots were found to be linear over the ranges of concentrations: 100.0-1000.0 ng/mL and 10.0-200.0 ng/mL for metoprolol and ivabradine, respectively. Validation of the procedure was performed using the International Council of Harmonization guidelines. Values of LODs were found to be 28.89, 2.80 ng/mL and LOQs were 87.56, 8.49 ng/mL for metoprolol and ivabradine, respectively. As the two drugs are co-administered safely and effectively to reduce heart rate, angina attacks, the current methodology is utilized for the concurrent analysis of them in their single ingredient pharmaceutical preparations, synthetic mixtures, and biological fluids. The designed method, being cost-effective and simple procedure, is the first method for metoprolol and ivabradine simultaneous analysis. The results agreed statistically with the comparison methods.

Four chemometric spectrophotometric methods for simultaneous estimation of amlodipine besylate and olmesartan medoxomil in their combined dosage form

For determination of amlodipine besylate (AML) and olmesartan medoxomil (OLM) at the same time, four UV chemometric spectrophotometric techniques were created and tested in accordance with ICH standards. Method (I) was absorption subtraction method (ASM) using two wavelengths, one of which was of AML at 365 nm and the other was the isoabsorptive point of both drugs at 237 nm. Method (II) was ratio subtraction method (RSM) for determination of OLM at λ_max = 254 nm by taking the ratio spectrum and subtracting the constant values using 10 μg/mL of AML as a divisor in combination with extended ratio subtraction method (ERSM) to determine AML at λ_max = 239 nm using 10 μg/mL OLM as a divisor. Method (III) was dual wavelength method; the wavelengths used to determine OLM were 221 nm and 235 nm, while those used to determine AML were 246 nm and 259 nm. Method (IV) was the second order derivative (²D) spectrophotometric method at 219 nm for OLM and 227 nm for AML. The proposed approaches were used to achieve linearity in the concentration range of 2-25 μg/mL for both drugs. The approaches were found to be uncomplicated, reproducible, efficient, and cost-effective as well as they were successfully used to determine the cited drugs in both laboratory samples and commercial pharmaceutical formulations.